促卵泡激素δ用于卵巢刺激安全有效:RITA随机双盲安慰剂对照试验结果
在美国两项随机双盲安慰剂对照多中心试验(RITA-1和RITA-2)中,共1165例接受体外受精或卵胞浆内单精子注射的患者按10:1随机接受促卵泡激素δ或安慰剂。促卵泡激素δ组累计持续妊娠率在<35岁患者为64.0%、≥35岁患者为43.9%,安慰剂组均为0,证实优效性。作者结论为按母亲年龄给药的促卵泡激素δ是有效且安全的卵巢刺激治疗。
要点
- 促卵泡激素δ固定起始剂量:<35岁12 μg/d,≥35岁15 μg/d,前4天刺激后按需调整。
- 累计持续妊娠率:<35岁64.0% vs ≥35岁43.9%,差异分别为64.0%和43.9%。
- 新鲜周期卵巢过度刺激综合征发生率:<35岁3.8%,≥35岁2.4%。
核心结论
- 促卵泡激素δ按母亲年龄给药是体外受精/卵胞浆内单精子注射患者卵巢刺激的有效且安全治疗。
研究设计与样本
- 两项随机、双盲、安慰剂对照、平行组、多中心试验(RITA-1和RITA-2)。
- 共1165例患者:RITA-1中578例18-34岁女性,RITA-2中587例35-42岁女性,按10:1随机分配至促卵泡激素δ或安慰剂。
主要发现
- 促卵泡激素δ组累计持续妊娠率:<35岁(RITA-1)64.0% vs ≥35岁(RITA-2)43.9%,安慰剂组均为0。
- 与安慰剂的差异:RITA-1为64.0%(95%CI 56.9%-68.1%),RITA-2为43.9%(95%CI 37.0%-48.2%)。
- 促卵泡激素δ组累计活产率:<35岁62.5%,≥35岁42.4%。
- 新鲜移植周期持续妊娠率:<35岁49.5%,≥35岁34.8%;活产率分别为48.2%和33.9%。
- 冻融移植周期持续妊娠率:<35岁44.2%,≥35岁31.2%;活产率分别为42.8%和29.9%。
关键数值与推荐
- 促卵泡激素δ固定起始剂量:<35岁12 μg/d,≥35岁15 μg/d,前4天刺激后按需调整。
- 新鲜周期卵巢过度刺激综合征发生率:<35岁3.8%,≥35岁2.4%。
临床怎么用
- 作者结论认为促卵泡激素δ按母亲年龄给药是体外受精/卵胞浆内单精子注射患者卵巢刺激的有效且安全治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To demonstrate the efficacy and safety of follitropin delta (recombinant follicle-stimulating hormone produced from the human cell line PER.C6) for ovarian stimulation in patients aged 18-34 and 35-42 years undergoing in vitro fertilization or intracytoplasmic sperm injection treatment in the United States. DESIGN: Two randomized, double-blind, placebo-controlled, parallel-group, multicenter trials (RITA-1 and RITA-2). SUBJECTS: A total of 1,165 patients (578 women aged 18-34 years in RITA-1 and 587 women aged 35-42 years in RITA-2), randomized 10:1 to follitropin delta or placebo. INTERVENTION: Ovarian stimulation with follitropin delta at a fixed starting dose (12 μg/d for patients aged <35 years and 15 μg/d for patients aged ≥35 years) for the first 4 stimulation days and subsequent dose adjustments as needed, or placebo as a reference group, in a gonadotropin-releasing hormone antagonist cycle. MAIN OUTCOME MEASURES: Cumulative ongoing pregnancy rate after fresh and cryopreserved cycles initiated within 12 months from start of ovarian stimulation. RESULTS: The cumulative ongoing pregnancy rates with follitropin delta were 64.0% in patients aged <35 years (RITA-1) and 43.9% in patients aged ≥35 years (RITA-2) vs. 0 with placebo, thus establishing superiority of follitropin delta to placebo (RITA-1, difference, 64.0% [95% confidence interval, 56.9%-68.1%]; RITA-2, difference, 43.9% [95% confidence interval, 37.0%-48.2%]). The cumulative live birth rates with follitropin delta were 62.5% in patients aged <35 years and 42.4% in patients aged ≥35 years. In the fresh transfer cycle, the ongoing pregnancy rates with follitropin delta were 49.5% in patients aged <35 years and 34.8% in patients aged ≥35 years, and the live birth rates were 48.2% and 33.9%, respectively. In cryopreserved transfer cycles, the ongoing pregnancy rates with follitropin delta were 44.2% in patients aged <35 years and 31.2% in patients aged ≥35 years, and the live birth rates were 42.8% and 29.9%, respectively. The incidence rates of ovarian hyperstimulation syndrome in the fresh cycle were 3.8% in patients aged <35 years and 2.4% in patients aged ≥35 years after treatment with follitropin delta. CONCLUSION: Follitropin delta, dosed on the basis of maternal age, is an effective and safe therapeutic for ovarian stimulation in in vitro fertilization/intracytoplasmic sperm injection patients. TRIAL REGISTRATION: For RITA-1, NCT03740737 (ClinicalTrials.gov), registered on October 24, 2018, first subject enrolled on October 26, 2018. For RITA-2, NCT03738618 (ClinicalTrials.gov), registered on October 24, 2018, first subject enrolled on October 29, 2018.
引用
- Scheiber MD, Doody KJ, Foster ED, et al. Ovarian stimulation with follitropin delta is safe and effective: results from the RITA randomized, double-blind, placebo-controlled trials. Fertil Steril. 2025. PMID: 40714031. doi:10.1016/j.fertnstert.2025.07.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。